Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Hudes G et al. · 2007 · New England Journal of Medicine · Atlas ID HUD2007

What this study shows

Temsirolimus alone extended median overall survival to 10.9 months versus 7.3 months with interferon alfa in poor-prognosis metastatic kidney cancer; rash, hyperglycemia, and hyperlipidemia were more common with temsirolimus.

Abstract

ShowHide

Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.

Read the full abstract on PubMed →

At a glance

Evidence type H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type2 - Human Clinical Trial
Model systemHumans, phase III RCT (n=626)
JournalNew England Journal of Medicine
Year2007
Peer reviewedYes
Record last updated2026-08-22
SourceDOI 10.1056/NEJMoa066838 · PMID 17538086

Extracted findings

InterventionTemsirolimus (± interferon alfa)
TargetmTOR
ModelHuman – phase III RCT (n=626, poor-prognosis RCC)
EffectTemsirolimus improved overall survival vs interferon alfa in poor-prognosis metastatic renal-cell carcinoma

In the Atlas

Related topics

Renal cell carcinoma (RCC)mTORTemsirolimus

Answers that reference this study

More studies on this topic

Cite this paper

ShowHide 
Hudes, G., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa066838

@article{HUD2007,
  author       = {Hudes, G. and others},
  title        = {{Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma}},
  journal      = {New England Journal of Medicine},
  year         = {2007},
  doi          = {10.1056/NEJMoa066838},
  note         = {PMID: 17538086},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper. 

Barton, O. (2026). Oliver's mTOR Atlas (record HUD2007) [Data set]. https://mtor-atlas.org/study/HUD2007/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_HUD2007,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record HUD2007},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/HUD2007/},
  doi          = {10.5281/zenodo.22059963}
}